Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition useful for treating chronic myeloid leukemia

a technology of myeloid leukemia and pharmaceutical composition, which is applied in the direction of drug compositions, peptide sources, peptide/protein ingredients, etc., can solve the problems of poor prognosis of cml

Inactive Publication Date: 2004-01-08
COUNCIL OF SCI & IND RES
View PDF9 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0038] Yet another embodiment, the said composition may be administered for period ranging between at least four weeks and up to twelve weeks, and in case of relapse it can again can be administered to the subject without any toxicity.

Problems solved by technology

The prognosis of CML is also poor in spite of vast advancement of clinical medicine (1).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition useful for treating chronic myeloid leukemia
  • Pharmaceutical composition useful for treating chronic myeloid leukemia
  • Pharmaceutical composition useful for treating chronic myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0057] Preparation of Sodium Chlorogenate:

[0058] 4.7 kg of Piper betel leaves freshly collected, washed with distilled water and then cut into small pieces. Small pieces of leaves were gathered together and mixed with 1.0 litre of distilled water and thoroughly homogenized in a mixture blender. The homogenate was passed through a fine cheesecloth to filter out the large particles and the filtrate was collected. The process was repeated 2-3 times to have maximum yield. The combined filtrate was then centrifuged, the aliquot, a clear solution, was collected and lyophilised to a semi-solid mass, which was about 110 gm. Collected material was examined for biological activity i.e. destruction of CML cells. On observing its positive activity, purification was initiated. 10 gm of above-mentioned material was loaded on Sephadex LH-20 column and chromatographed with water, water-methanol (1:1) and methanol as eluent. Three different fractions thus obtained from three different solvent system...

example 2

[0060] The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen carbonate (024 g in 5 ml of water) solution. The solution was lyophilised to pure sodium chlogogenate (1.12 gm) and was tested for biological activity. Sodium chlorogenate prepared from chlorogenic acid which was either isolated from Piper betel or obtain commercially have similar structure and activity.

example 3

[0061] Culture of Bcr-Abl positive CML cell line (K562), peripheral blood cells of CML patients, Bcr-Abl-negative ALL cell line (Molt-4) and peripheral blood cells of CML patients. Cell count assays were performed by plating cells in the presence of regular growth medium with or without indicated amount of extract, fraction, purified compound and its sodium salt. Each day, viable cells were counted as assessed by exclusion of trypan blue.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and / or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

Description

[0001] This application claims benefit of U.S. Provisional application No. 60 / 393,750 filed on Jul. 8, 2002 and is a Continuation-In-Part of an application entitled "An Herbal Molecule As Potential Anti-leukemic Drug" filed Jan. 9, 2003.[0002] This invention relates to treatment of chronic myeloid leukemia (CML) by a composition comprising analogs of chlorogenic acid and / or its salts such as sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.[0003] Chronic myeloid leukemia is lethal, there is no drug directing towards the destruction of the leukemic cells, and these cells poorly respond to chemotherapy which is always non-specific thus adversely affecting normal cells. Unique property of the therapy with NaChl is the killing of myeloid cancer cells leaving other normal cells unaffected.BACKGROUND AND PRIOR ART REFERENCES[0004] Myeloid leukemia is usually subdivided into two groups: Acute Myeloid Leukemia (AML) and Ch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61K31/215A61K31/216A61K31/225A61K31/235A61K31/366A61K31/70A61K31/716A61K36/67A61K45/06
CPCA61K31/192A61K31/215A61K31/216A61K31/235A61K31/70A61K31/716A61K45/06A61K2300/00A61K31/225A61K31/366A61K36/67
Inventor BANDYOPADHYAY, SANTUPAL, BIKAS CHANDRABHATTACHARYAY, SAMIRMONDAL, SWAPANMANDAL, CHHABINATHKONAR, ADITYAROY, KESHAB CHANDRABISWAS, TANUSREEBANDYOPADHYAY, GAUTAM
Owner COUNCIL OF SCI & IND RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com